484 related articles for article (PubMed ID: 33664994)
1. Targeting the epigenome in in-stent restenosis: from mechanisms to therapy.
Yang X; Yang Y; Guo J; Meng Y; Li M; Yang P; Liu X; Aung LHH; Yu T; Li Y
Mol Ther Nucleic Acids; 2021 Mar; 23():1136-1160. PubMed ID: 33664994
[TBL] [Abstract][Full Text] [Related]
2. The adipokine vaspin is associated with decreased coronary in-stent restenosis in vivo and inhibits migration of human coronary smooth muscle cells in vitro.
Kastl SP; Katsaros KM; Krychtiuk KA; Jägersberger G; Kaun C; Huber K; Wojta J; Speidl WS
PLoS One; 2020; 15(5):e0232483. PubMed ID: 32392256
[TBL] [Abstract][Full Text] [Related]
3. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
[TBL] [Abstract][Full Text] [Related]
4. Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study.
Alfonso F; Cuesta J; Pérez-Vizcayno MJ; García Del Blanco B; Rumoroso JR; Bosa F; Pérez de Prado A; Masotti M; Moreno R; Cequier A; Gutiérrez H; García Touchard A; López-Mínguez JR; Zueco J; Martí V; Velázquez M; Morís C; Bastante T; García-Guimaraes M; Rivero F; Fernández C;
JACC Cardiovasc Interv; 2017 Sep; 10(18):1841-1851. PubMed ID: 28866036
[TBL] [Abstract][Full Text] [Related]
5. [Progress in genetic and epigenetic research on in-stent restenosis after percutaneous coronary interventions].
Kang YH; Lao HY; Yu XY; Chen JY; Zhong SL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Feb; 29(1):38-42. PubMed ID: 22311489
[TBL] [Abstract][Full Text] [Related]
6. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
[TBL] [Abstract][Full Text] [Related]
7. Increased serum TREM-1 level is associated with in-stent restenosis, and activation of TREM-1 promotes inflammation, proliferation and migration in vascular smooth muscle cells.
Wang F; Li C; Ding FH; Shen Y; Gao J; Liu ZH; Chen JW; Zhang RY; Shen WF; Wang XQ; Lu L
Atherosclerosis; 2017 Dec; 267():10-18. PubMed ID: 29080545
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Efficacy of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With In-Stent Restenosis (from the RIBS IV and V Randomized Clinical Trials).
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; Masotti M; López-Minguez JR; Iñiguez A; Zueco J; Velazquez M; Cequier A; Lázaro-García R; Martí V; Moris C; Urbano-Carrillo C; Bastante T; Rivero F; Cárdenas A; Gonzalo N; Jiménez-Quevedo P; Fernández C;
Am J Cardiol; 2016 Feb; 117(4):546-554. PubMed ID: 26725102
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
[TBL] [Abstract][Full Text] [Related]
10. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
[TBL] [Abstract][Full Text] [Related]
11. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells.
Shen Y; Li C; Zhang RY; Zhang Q; Shen WF; Ding FH; Lu L
Int J Cardiol; 2017 Feb; 228():129-136. PubMed ID: 27863353
[TBL] [Abstract][Full Text] [Related]
12. Refractory In-Stent Restenosis: Improving Outcomes by Standardizing Our Approach.
Waksman R; Iantorno M
Curr Cardiol Rep; 2018 Oct; 20(12):140. PubMed ID: 30350271
[TBL] [Abstract][Full Text] [Related]
13. Angiography and Optical Coherence Tomography Assessment of the Drug-Coated Balloon ESSENTIAL for the Treatment of In-Stent Restenosis.
de la Torre Hernández JM; Garcia Camarero T; Lozano Ruiz-Poveda F; Urbano-Carrillo CA; Sánchez Pérez I; Cano-García M; Saez R; Andrés Morist A; Molina E; Pinar E; Torres A; Lezcano EJ; Gutierrez H; Arnold RJ; Zueco J
Cardiovasc Revasc Med; 2020 Apr; 21(4):508-513. PubMed ID: 31401071
[TBL] [Abstract][Full Text] [Related]
14. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs.
He YH; Wang XQ; Zhang J; Liu ZH; Pan WQ; Shen Y; Zhu ZB; Wang LJ; Yan XX; Yang K; Zhang RY; Shen WF; Ding FH; Lu L
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):717-729. PubMed ID: 28183701
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin promotes intimal hyperplasia and contributes to in-stent restenosis: Role of an αVβ3/FAK dependent YAP pathway.
He Y; Zou P; Lu Y; Jia D; Li X; Yang H; Tang L; Zhu Z; Tu T; Tai S; Xiao Y; Chen M; Lu L; Zhou S
J Mol Cell Cardiol; 2020 Feb; 139():1-13. PubMed ID: 31958462
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of drug-eluting stent and conventional therapies in coronary heart disease patients with in-stent restenosis: a meta-analysis.
Sun Y; Li L; Su Q; Lu Y
Cell Biochem Biophys; 2014 Jan; 68(1):211-29. PubMed ID: 23784750
[TBL] [Abstract][Full Text] [Related]
17. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
[TBL] [Abstract][Full Text] [Related]
18. Noncoding RNAs in Vascular Cell Biology and Restenosis.
Efovi D; Xiao Q
Biology (Basel); 2022 Dec; 12(1):. PubMed ID: 36671717
[TBL] [Abstract][Full Text] [Related]
19. Activation of Peroxisome Proliferator-Activated Receptor-δ as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis.
Hytönen J; Leppänen O; Braesen JH; Schunck WH; Mueller D; Jung F; Mrowietz C; Jastroch M; von Bergwelt-Baildon M; Kappert K; Heuser A; Drenckhahn JD; Pieske B; Thierfelder L; Ylä-Herttuala S; Blaschke F
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1534-48. PubMed ID: 27283742
[TBL] [Abstract][Full Text] [Related]
20. Update on In-stent Restenosis.
El-Omar MM; Dangas G; Iakovou I; Mehran R
Curr Interv Cardiol Rep; 2001 Nov; 3(4):296-305. PubMed ID: 11696295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
